SAN DIEGO, CA--(Marketwire - November 13, 2008) - Lpath, Inc. (OTCBB: LPTN) today announced that the laboratory of Peter Campochiaro, MD at Johns Hopkins University School of Medicine(1) recently published peer-reviewed findings of a research study of iSONEP™, Lpath's Phase 1 anti-S1P antibody, demonstrating promising results in various animal models of ocular disorders.
